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Background: Oral cancer is a public health issue worldwide. Oral potentially malignant disorders (OMPDs) are 
lesions of the oral mucosa that are predisposed to malignant transformation. The mainstay of OMPDs treatment 
around the world is now the carbon dioxide (CO2) laser but the reported recurrence and malignant transformation 
rates vary widely in the literature. We aimed to estimate the recurrence and the malignant transformation rates 
of OPMDs treated with CO2 laser at the University Hospital of Bordeaux, in France, from 2010 to 2014, and to 
identify associated factors with recurrence or malignant transformation. 
Study design: We conducted a retrospective study in patients with a minimum follow-up of 12 months. Collected 
variables included characteristics of the patients (gender, age, alcohol and tobacco consumption, previous diagno-
sis of graft-versus-host disease, previous treatments for OPMD or for upper aerodigestive tract cancers and human 
immunodeficiency virus infection), characteristics of the lesions (form, colour, size, location, degree of dysplasia), 
laser treatment outcome (complications, recurrence, malignant transformation). 
Results: Twenty-five patients were included. Mean follow-up was 28.9 months. Recurrence was observed in 11 pa-
tients (44%). Annual recurrence rate was 18.3% and annual malignant transformation rate was 1.7%. Hyperplasia 
without dysplasia was the only factor found to be statistically associated with recurrence. 
Conclusions: Our results suggest that OMPDs treated by CO2 laser vaporization have high recurrence rates, particularly 
those presenting hyperplasia. A standardized definition of recurrence would be necessary for inter-study comparisons. 
Long-term follow-up is recommended in order to detect and treat squamous cell carcinoma in its early stages.
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Introduction
Cancer is becoming the first cause of premature deaths 
among noncommunicable diseases according the World 
Health Organization (WHO). An estimated 300 373 new 
cases of cancers of the lip and oral cavity occurred world-
wide in 2012, with 145 353 deaths (WHO). Most oral 
cancers are oral squamous cell carcinoma. The main risk 
factors for oral cancer are tobacco smoking and chew-
ing and alcohol consumption. Prognosis of the oral can-
cer decreases with advanced disease at presentation. The 
five-years survival rates are approximately 80% for stage 
I cancers, and 20% for advanced diseases (stages III/IV) 
(1). The treatment of oral cancer of early stage permits to 
improve survival and to reduce morbidity in patients (2). 
Unfortunately worldwide the half of patients present with 
a late stage of disease (1). Management of oral poten-
tially malignant disorders (OMPDs) to prevent malignant 
transformation (primary prevention, not evidence-based 
to date (3)) or to detect very early cancer (secondary pre-
vention) is worthy of consideration (2). 
OMPDs are lesions of the oral mucosa that are predis-
posed to malignant transformation. The most common 
OMPD in France include leukoplakia (homogeneous 
leukoplakia, nonhomogeneous leukoplakia and prolif-
erative verrucous leukoplakia (PVL)), lichen planus, 
lichenoid dysplasia and actinic cheilitis (Table 1, 4-10). 
Standard care of these lesions are surgical removal of 
the lesion (cold-knife, laser excision and vaporization, 
cryosurgery, photodynamic therapy), medical treat-
ment (topical or systemic), cessation of risk activities 
(smoking and alcohol) and surveillance (3). Carbon di-
oxide (CO2) is now the mainstay of treatment of OPMD 
around the world (11), it has been previously reported to 
be a safe and an effective tool (12-15). The reported re-
currence and malignant transformation rates vary wide-
ly after treatment of OPMDs because of differences in 
terms of lesions treated, treatment, follow-up time and 
definition of recurrence, which leads to difficulties in 
informing patients (9-11,13,14,16-18).
The objective of the present study was to estimate the 
recurrence and the malignant transformation rates of 
OPMDs treated with CO2 laser at the University Hos-
pital of Bordeaux, in France, from 2010 to 2014, and to 




This retrospective study included all patients treated with 
CO2 laser for oral potentially malignant disorders (OPMD) 
at the University Hospital of Bordeaux from 2010 to 2014 
with a minimum follow-up of 12 months. Follow-up start-
ed from the date of first laser treatment and ended on the 
date of the last visit to the hospital in 2014 or on the date of 
malignant transformation. Written informed consent was 
obtained from each patient. The study was approved by 
the French ethics committee Comité de Protection des Per-
sonnes Sud-Ouest et Outre Mer III.
- Laser treatment
All included OPMDs were treated with laser vaporiza-
tion after incisional biopsies. Lesions with severe dys-
plasia were not included because they were surgical 
excised to allow histological examination of the whole 
lesion. The CO2 laser system was a Lumenis ® 40C 
(Lumenis Inc., CA, USA). Laser wavelength was 10966 
nm, the beam was used at focal spot 4, power from 10 
to 20W, in a noncontact application. The same surgeon 
treated all patients. Treatment was performed under lo-
cal anaesthesia (articaïne with epinephrine 1:100000). 
Lesions were delimited with a surgical marker with a 
2-3 mm margin when feasible. Paracetamol, alone or 
combined with codeine, was prescribed for pain control 
after treatment. 
- Data collection
• Patients: The characteristics of the patients treated 
with laser vaporization included the demographic cha-
racteristics (gender, age), the risk factors (alcohol and 
tobacco consumption (user, non-user, or former user), 
previous diagnosis of graft-versus-host disease, previ-
ous treatments for OPMD or for upper aerodigestive 
tract cancers and human immunodeficiency virus infec-
tion (5)) and the follow-up (number of medical appoint-
ments and laser sessions). 
• Oral potentially malignant disorders: The OMPD in-
cluded were homogeneous leukoplakia, nonhomoge-
neous leukoplakia, proliferative verrucous leukoplakia 
(PVL), lichen planus, lichenoid dysplasia and actinic 
cheilitis (Table 1). The lesions were described according 
to their form (unifocal, multiple sites, symmetric multiple 
sites), colour (white, red, black), size of greatest dimen-
sion (under 2 cm, from 2 to 4 cm, over 4 cm), and location 
(tongue, upper lip, lower lip, oral commissures, upper al-
veolus and gingiva, lower alveolus and gingiva, floor of 
mouth, buccal mucosa, hard palate and soft palate). The 
degree of dysplasia was classified as hyperplasia without 
dysplasia, or with dysplasia (mild, moderate).
• Laser treatment outcome: 
◦ Complications: All complications after laser treatment 
such as necrosis of the treated area, granuloma onset 
were taken into account. 
◦ Recurrence: Local recurrence was defined as an 
OMPD arising within the borders of the treated area af-
ter complete remission. Small white lesions arising be-
tween laser sessions were not considered as recurrence. 
Recurrence time was the period in months from the first 
laser session until the appearance of a recurrent OMPD. 
◦ Annual recurrence rate was calculated as (15,16):
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖 𝑡𝑡ℎ𝑒𝑒 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜𝑤𝑤-𝑢𝑢𝑢𝑢 𝑖𝑖𝑖𝑖 𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 ∗ 100	
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◦ Malignant transformation: Malignant transformation 
was defined as the development of oral squamous cell 
carcinoma or carcinoma in situ at the site of a previously 
treated OPMD. Malignant transformation time was the 
period in months from the first laser session until the 
development of oral squamous cell carcinoma or carci-
noma in situ. Annual malignant transformation rate was 
calculated with the same formula using the total number 
of malignant transformations instead of the total num-
ber of recurrences.
◦ Clinical outcome categories: At the time of data ex-
traction, patients were assigned to one of the 4 clinical 
outcome categories: complete remission (the absence 
of OPMD), under treatment or scheduled for treatment 
(achieving treatment or additional treatment required), 
stable on surveillance (OPMD persisting despite treat-
ment) and malignant transformation (confirmed histo-
logically). 
- Data extraction: Data were extracted from medical 
records. Patients with missing risk factor data were 
contacted and asked by phone. When available, photo-
graphs were used to check the clinical characteristics of 
the lesions reported on medical records.
• Data analysis
Frequencies and percentages were calculated for quali-
tative variables. Mean, standard deviation (SD), and 
minimum (min) and maximum (max) were calculated 
for quantitative variables. The log-rank test and Ka-
plan-Meier survival curves were used to compare the 2 
groups of patients (with recurrence or malignant trans-
formation and without recurrence or malignant trans-
formation) regarding the potential risk factors for re-
currence: gender, age (in 2 categories, under 65 and 65 
or over), tobacco and alcohol use, previous treatment, 
graft-versus-host disease and human immunodeficien-
cy virus infection, lesion shape, colour, size, location, 
clinical and pathological diagnosis (mild and moderate 
dysplasia cases were grouped together). Tests were con-
sidered statistically significant if the p-value was <0.05. 
RStudio 0.98.1062 (RStudio, Inc.) was used for tests and 




Of 46 patients examined for an OMPD and treated 
with laser vaporization from 2010 to 2014 at the Uni-
versity Hospital of Bordeaux, 21 were excluded because 
they did not have at least 12 months of follow-up at the 
time of data extraction (September 2014) (15,16). The 
remaining 25 patients were included: 14 men and 11 
women, mean age 66.4 years (SD 11.1, min 49, max 
90) (Table 2). Seventeen patients (68.0%) reported a to-
bacco use (user and former user), 10 (43.5%) an alcohol 
use, and 3 (14.3%) a tobacco and alcohol use. Previous 
treatments for OPMD or for upper aerodigestive tract 
cancers were found in 5 cases (20.0%), GVH and HIV 
in 2 cases (8.0%). Follow-up ranged from 12.3 to 50.7 
months (mean 28.9, SD 12.6). The mean number of 
medical appointments per patient was 8.3 (SD 3.5, min 
2, max 17). The mean number of laser sessions was 4 
(SD 2.2, min 1, max 9). 
2/ Oral potentially malignant disorders
These 25 patients presented 25 OMPDs. Lesions were 
mainly unifocal (n=15, 60.0%), white (n=18, 75.0%), 
from 2 to 4 cm (n=9, 40,9%), at multiple site (n=10, 
40%). 6 clinical diagnosis were encountered: homoge-
neous leukoplakia (n=11, 44.0%), nonhomogeneous leu-
koplakia (n=3, 12.0%), proliferative verrucous leuko-
plakia (PVL) (n=5, 20.0%), actinic cheilitis (n=1, 4.0%), 
lichen planus (n=3, 12.0%) and lichenoid dysplasia (n=2, 
8.0%) (Table 3). For the anatomopathologic diagnosis, 
11 lesions were hyperplasia without dysplasia (44.0%) 
and 14 were with mild or moderate dysplasia (56.0%). 
3/ Laser treatment outcome
• Complications: Nine patients had minor complications 
(36%), 5 had granulomas (20.0%), 2 had small bone ne-
crosis which resolved spontaneously (8.0%), 1 had delayed 
wound healing (4.0%) and 1 had a sclerotic scar (4.0%).
• Recurrence: Recurrence after laser treatment was ob-
served in 11 of the 25 patients (44.0%). All recurrences 
appeared between 5.4 and 39.7 months after the first 
laser session (mean 19.7, SD 11.1; Fig.1). Annual recur-
rence rate was 18.3%. Table 3 shows that most recurrent 
lesions were unifocal, 70.0% were white, 44.4% were 
2-4 cm in size, 45.5% were located at multiple sites, and 
54.5% were homogeneous leukoplakias. More than half 
of recurrent lesions initially had no dysplasia. Recur-
rence was managed by surveillance in 5 cases and by 
CO2 laser excision or vaporization in 6.
• Malignant transformation: In 1 of 25 treated patients 
(4%), malignant transformation occurred during the 
48th month after the first laser treatment session. Annu-
al malignant transformation rate was 1.7%. The patient 
with an initial diagnosis of actinic cheilitis and moder-
ate dysplasia was later diagnosed with carcinoma in situ 
and was referred to the oncology department, where he 
is currently undergoing treatment
Clinical outcome categories: Excluding the lesion with 
malignant transformation, at the time of time of data 
extraction, 13 lesions (52%), including 4 that recurred, 
reached complete remissions (Fig.2), 7 (28%) were sta-
ble on surveillance and 4 (16%) were under treatment or 
scheduled for treatment.
4/ Factors associated with recurrence or malignant 
transformation
Hyperplasia without dysplasia was the only factor 
found to be statistically associated with recurrence (p-
value=0.02; Table 3). No other factor/characteristic was 
found to be statistically associated with recurrence/ma-
lignant transformation (Tables 2 and 3). 
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Variables N (%) N (%) N (%) N  
Gender        0.87 
Male 14 56.0 6 54.5 8 57.1 1  
Female 11 44.0 5 45.5 6 42.9 0  
Age (years)        0.42 
< 65 12 48.0 3 27.0 9 64.0 0  
 ≥65 13 52.0 8 73.0 5 36.0 1  
Average [SD] 66.4 [11.1] 69.8 [11.9] 63.7 [10.0] 82.6  
Median  
Quartile range  
65.0 
56.0 – 75.0 
68.0 
65.5 – 77.0 
61.5 
56.0 – 65.7 
- 
-  
Min – Max 49.0 – 90.0 49.0 – 90.0 55.0 – 88.0 -  
Tobacco 
consumption        0.75 
User 8 32.0 2 18.2 6 42.9 0  
Former user 9 36.0 4 36.4 5 35.7 0  
Non-user 8 32.0 5 45.5 3 21.4 1  
Alcohol consumption        0.33 
User 9 39.1 5 45.5 4 33.3 0  
Former user 1 4.3 0 0 1 8.3 0  
Non-user 13 56.5 6 54.5 7 58.3 0  
Unknown 2 - 0 - 2 - 1  
Tobacco and Alcohol 
consumption        0.57 
User 3 14.3 1 11.1 2 16.7 0  
Former user 0 0 0 0 0 0 0  
Non-user 18 85.7 8 88.9 10 83.3 1  
Unknown 4 - 2 - 2 - 0  
GVH        0.71 
Yes 2 8.0 1 9.1 1 7.1 0  
Previous treatment*        0.14 
Yes 5 20.0 1 9.1 4 28.6 0  
HIV        0.11 
Yes 2 8.0 0 0 2 14.3 0  
	
Table 2. Characteristics of patients diagnosed with oral potentially malignant disorders (OPMDs), recurrent OPMDs and oral squamous 
cell carcinoma (OSCC). Centre Hospitalier Universitaire de Bordeaux, France, 2010-2014.
*Previous treatments for OPMD or for upper aerodigestive tract cancers
GVH: Graft Versus Host disease
HIV: Human Immunodeficiency Virus 
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Table 3. Characteristics of oral potentially malignant disorders (OPMDs), recurrences and oral squamous cell carcinomas (OSCC) diag-
nosed and treated among 25 patients. Centre Hospitalier Universitaire de Bordeaux, France, 2010-2014.
PVL: Proliferative verrucous leukoplakia








Variables N (%) N (%) N (%) N
Form 0.33
Unifocal 15 60.0 6 54.5 9 64.3 1
Multiple sites 10 40.0 5 45.5 5 35.7 0
Colour 0.80
White 18 75.0 7 70.0 11 78.6 0
Red 1 4.2 0 0 1 7.1 1
White and red 5 20.8 3 30.0 2 14.3 0
Unknown 1 - 1 - 0 - 0
Size 0.97
< 2 cm 5 22.7 2 22.2 3 23.1 1
2 – 4 cm 9 40.9 4 44.4 5 38.5 0
> 4 cm 8 36.4 3 33.3 5 35.5 0
Unknown 3 - 2 - 1 - 0
Location 0.61
Tongue 5 20.0 3 27.3 2 14.3 0
Lower lip 3 12.0 0 0 3 24.4 1
Upper or lower alveolus and 
gingiva 2 8.0 0 0 2 14.3 0
Buccal mucosa 2 8.0 1 9.1 1 7.1 0
Hard palate 1 4.0 1 9.1 1 7.1 0
Intermaxillary 
commissures 2 8.0 1 9.1 1 7.1 0
Multiple sites 10 40.0 5 45.5 5 35.7 0
Clinical diagnosis 0.76
Homogenous leukoplakia 11 44.0 6 54.5 5 35.7 0
Non-homogenous 
leukoplakia 3 12.0 0 0 3 21.4 0
PVL 5 20.0 2 18.2 3 21.4 0
Actinic cheilitis 1 4.0 0 0 1 7.1 1
Lichen planus 3 12.0 1 9.1 2 14.3 0




dysplasia 11 44.0 7 63.6 4 28.6 0
Mild or moderate dysplasia 14 56.0 4 36.4 10 71.5 1
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Fig. 1. (a) Homogeneous leukoplakia on the tongue mucosa of a 
77-year-old female patient. (b) Treatment by CO2 laser vaporization. 
(c) Persistent lesion 4 months after laser vaporization. 
Fig. 2. (a) Non-homogeneous leukoplakia on the tongue mu-
cosa of a 57-year-old female patient. (b-c) Treatment by CO2 
laser vaporization. (d) Complete remission 1 year after laser 
vaporization. 
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Discussion
We considered all OPMDs diagnosed except those 
with severe epithelial dysplasia which were surgically 
excised (16). In the other lesions, recurrence after la-
ser treatment occurred in 44% of the patients dur-
ing a mean follow-up of mean 28.9 months. Our data 
showed a high rate of recurrence which was similar to 
that reported in some studies with CO2 laser vaporiza-
tion (Table 4): Brouns et al. reported a recurrence rate 
of 40% for oral leukoplakias in a mean period of 61.9 
months (16), Pedrosa et al. observed recurrence rates 
of 40.7% for oral leukoplakias in a mean period of 43.8 
months (17) and Mücke et al. reported a recurrence fre-
quency of 38.2% for erosive lichen planus in a mean 
period of 42.7 months (9). In fact, the recurrence rate 
varies widely for CO2 laser vaporization from 9.9% to 
44% (9-11,13,14,16-20); Table 4). This variation can be 
attributed to the differences in terms of lesions treated, 
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et al. (20) Netherlands 1991 103 Leukoplakia 63.6 9.7% 0%
Huerta et al. 







et al. (11) Australia 2005 73 Leukoplakia 47.2 28.9% 7.3%
Van der Hem 
et al. (13) Netherlands 2005 282 Leukoplakia 52 9.9% 1.1%
Deppe et al. 






Brouns et al. 
(16) Netherlands 2013 35 Leukoplakia 61.9 40.0% 14.2%
Pedrosa 
et al. (17) Portugal 2015 59 Leukoplakia 43.8 40.7%
10.2 %
Mücke et al. 
(9) Germany 2015 68
Erosive lichen 
planus 42.7 38.2% 2.9%
Mogedas 
et al. (18) Spain 2015 65 Leukoplakia 15 33.8% 15.4%
Present 
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treatment modalities, follow-up time and above all defi-
nition of recurrence. There is no consensual definition 
for recurrence in the literature. Some authors define it 
as a lesion occurring at the primary lesion site after a 
confirmed remission period (17). Others note that only 
one-third of recurrences occur at the same site and con-
sequently define recurrence as being a new lesion recur-
ring after excision that possibly differs from the initial 
one (12). This definition favours the use of the term 
“disorder” instead of lesion, especially for leukopla-
kia, recognizing the fact that recurrence (or malignant 
transformation) can occur elsewhere in the mouth or in 
the upper aerodigestive tract (7). Different definitions of 
recurrence are a barrier to a clear comparison between 
studies. Recurrence could also result from a concept of 
field changes or cancerization: genetic changes wide-
spread in the oral mucosa, triggered by environmental 
factors (e.g. smoking and alcohol), leading to higher de-
grees of dysplasia and to development of cancer (21). 
This could explain the high recurrence rate observed in 
this study. The role of field cancerization is especially 
important in widespread lesions like PVL, as demons-
trated by Bagán et al. (22). The surgical margins are 
more likely to be within an area of field change: as area 
is wider, with clinically normal epithelium, recurrence 
is more likely to occur.
We found no statistically significant association between 
exposure to patients’ characteristics and recurrence, 
except for the pathological diagnoses. Kaplan-Meier 
estimates indicated that, after 30 months of follow-up, 
the probability of being free from recurrence was ap-
proximately 75% for mild or moderate dysplasia lesions 
and about 50% for hyperplasia without dysplasia. In the 
literature, variables significantly associated with recur-
rence of OPMD treated with CO2 laser vaporization are 
alcohol consumption and previous malignancy (11), gin-
giva location (18) and moderate to high-grade dysplasia 
(17). Our contradictory findings can be explained by 
the fact that severe dysplasia was not included in the 
study (so the remaining dysplasia had a low risk of recu-
rrence) and our small sample size. A greater sample size 
is needed to increase the chance of finding a significant 
association, but is difficult to reach in a single-centre 
study, as potentially malignant lesions are rare (<5%). 
The ultimate aim of the management of OMPD is the 
prevention of oral cancer. To date, there is no evidence 
that a treatment for OPMD is effective for preventing the 
development of oral cancer (lack of Randomised Con-
trol Trial (RCT) with placebo or without treatment) (3). 
Holmstrup et al. reported in a retrospective study the 
long-term treatment outcome of 269 oral premalignant 
lesions (leukoplakia and erythroplakia) with or without 
surgical intervention by scalpel and they concluded that 
surgical intervention did not prevent malignant trans-
formation (23). Although it yet remains unproven the 
surgical removal (including laser surgery) of the clini-
cally altered tissue it is widely recommended (12). Our 
results indicate a malignant transformation rate of 4% in 
during a mean follow-up of 2.4 years (annual malignant 
transformation rate of 1.7%). It is in accordance with the 
malignant transformation rates of less than 15.4 % for 
OMPD treated with CO2 laser vaporization reported in 
the literature (9-11,13,14,16-20); Table 4). Nevertheless, 
annual malignant transformation rates differ from one 
OPMD to another (2% to 3% for leukoplakia, less than 
0.5% for lichen planus (7), unknow for actinic cheilitis 
(5), Table 1) and the diversity of the lesions included in 
our study making comparison difficult. A growing body 
of evidence suggests that effort should be made to dif-
ferentiate oral lichen planus from oral lichenoid lesions, 
the latter showing a higher risk of malignant transfor-
mation. Differential diagnosis is considered hard (7).  In 
this study we did not differentiate oral lichen planus and 
oral lichenoid lesions. We used the term ‘lichenoid dys-
plasia’ to determine lichenoid lesions presenting epithe-
lial dysplasia, but this term is confusing (5,7) and more 
studies are needed to address the concept of lichenoid 
dysplasia in order to resolve any controversies related to 
the malignant potential of oral lichen planus.
The most relevant characteristics that increase the risk 
of malignant transformation are nonhomogeneous sub-
type, size (>4 cm), presence of dysplasia and location 
on the tongue or floor of the mouth (7). Advanced age 
and female sex are also important determinants in as-
sessing malignant potential (24). In the present study, 
the association between these characteristics and malig-
nant transformation was not tested because of the small 
number of cases. However, the literature shows that ces-
sation of smoking after surgical treatment considerably 
reduces the risk of malignant transformation (7,25)  and 
that patients should be encouraged to quit and referred 
to smoking cessation programs if necessary. 
After CO2 laser vaporization, we noted minor complica-
tions in 9 cases (36%). Other researchers did not indi-
cate the onset of complications (9,10,13,19), reported no 
complication (14,17,20) or significantly lower complica-
tion rates ranging from 2.9% to 7.7% (11,16,18). Howev-
er, there is no standardized definition of a complication 
after treatment, so these findings may include different 
events. Exceptional cases of mental nerve paresthesia 
and anesthesia were reported (11,16).  
Our study was not designed to evaluate the effect of the 
nature of the treatment. A comparative study with bi-
lateral leukoplakia (one side of the lesion excised using 
CO2 laser and the other side using scalpel) has shown 
that advantages of  laser include less bleeding intra op-
eratively, less swelling and scarring post-operatively 
than scalpel (26). There was no significant difference 
in terms of post-operative pain. No RCT is available 
to compare CO2 laser with conventional surgery in 
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terms of recurrence and malignant transformation rate. 
Brouns et al. 2014 have managed 144 patients with oral 
leukoplakia with surgical excision, CO2 laser vaporisa-
tion or observation only but was no unable to compare 
the treatment results due to their different indications 
(15). CO2 laser treatment modalities are vaporization 
i.e. a selective removal of affected epithelium, exci-
sion or a combination of both. The only comparative 
study available on laser evaporation and excision had 
used two different lasers for the treatment of leukopla-
kia (Nd:YAG and CO2 respectively) which did not allow 
to compare the laser treatment modalities (27). Laser 
vaporization appears suitable for wide lesions or mul-
tiple lesions at sites that were less amenable for surgical 
excision like floor of the mouth and mucobuccal folds 
(15,27). It permits to limit the post-operative discom-
fort and the functional problems induced by excision 
in this case (13,27). The main disadvantage is that va-
porization does not allow histological examination of 
the whole lesion (13,27). Incisional biopsies performed 
prior to treatment may not represent the entire lesion 
and so some dysplasia may have been missed, resulting 
in a measurement bias (23). Besides risk factors, defini-
tion criteria and follow-up period, the type of laser and 
the surgical technique used may also be related to treat-
ment outcome. RCT are needed to better establish the 
effectiveness of the different treatments for OPMD (3). 
This study has several limitations. First, this is a retro-
spective study. It is based on complete records from the 
archives of the University Hospital of Bordeaux. Sec-
ond, the sample size is small (25 patients) but similar to 
that reported in some studies with CO2 laser vaporiza-
tion (10,16) (Table 4). This is due to the characteristics 
of the studied lesions themselves which are rare (<5%) 
and require further follow-up to observe a potential re-
currence or malignant transformation. We had a small 
sample size despite a four-year screening period, pro-
viding a small power to identify associated factors, but 
on the other hand, we had data of good quality from 
a homogeneous sample (severe dysplasia excluded, all 
treated by CO2 Laser by the same surgeon) followed-
up at least 12 months as indicated by Brouns et al. (14, 
16). These lesions should become even rarer as the 
prevalence of tobacco smoking is declining worldwide 
(WHO), pointing out the need for future systematic re-
views and meta-analyses, in which our study can con-
tribute, and collaborative multicentre studies.
In conclusion, we noted a high recurrence rate of OMP-
Ds treated with CO2 laser, particularly in those with 
hyperplasia. Randomized clinical trials should be used 
to evaluate the outcome of different treatment methods 
and multicentre studies could increase the power of sta-
tistical analyses. Standardized recurrence criteria are 
necessary for more accurate comparisons between stud-
ies. Long-term follow-up programmes are important to 
detect malignant transformation in its early stages and 
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